Comparison of conference abstracts and presentations with full-text articles in the health technology assessments of rapidly evolving technologies

Health Technology Assessment

Volumn 10, Issue 5, 2006, Pages

  Dundar, Y ^a   Dodd, S ^a   Dickson, R ^a   Walley, T ^a   Haycox, A ^a   Williamson, P R ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

7 HEXANOLYTAXOL; ALPHA INTERFERON; DACTINOMYCIN; DOCETAXEL; DONEPEZIL; ETANERCEPT; EVEROLIMUS; FLUDARABINE; GALANTAMINE; GEMCITABINE; INFLIXIMAB; IRINOTECAN; METHOTREXATE; NAVELBINE; OXALIPLATIN; PACLITAXEL; PIOGLITAZONE; RALTITREXED; RAPAMYCIN; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RIBAVIRIN; RILUZOLE; RITUXIMAB; RIVASTIGMINE; SIBUTRAMINE; TAXANE DERIVATIVE; TEMOZOLOMIDE; TETRAHYDROLIPSTATIN; TOPOTECAN; UNCLASSIFIED DRUG; UNINDEXED DRUG; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY; TNFR FC FUSION PROTEIN; TNFR-FC FUSION PROTEIN; TUMOR NECROSIS FACTOR RECEPTOR;

ALZHEIMER DISEASE; B CELL LEUKEMIA; BREAST CANCER; CLINICAL TRIAL; COCHRANE LIBRARY; COLORECTAL CANCER; CORONARY ARTERY DISEASE; CORONARY STENT; COST EFFECTIVENESS ANALYSIS; DEFIBRILLATOR; DRUG ELUTING STENT; ELECTRONIC DATA INTERCHANGE; FOLLICULAR LYMPHOMA; GLIOBLASTOMA; HEART ARRHYTHMIA; HEPATITIS C; HUMAN; LUNG NON SMALL CELL CANCER; LYMPHATIC LEUKEMIA; MEDICAL AUDIT; MEDICAL DOCUMENTATION; MEDICAL LITERATURE; MEDICAL RESEARCH; MEDICAL TECHNOLOGY; META ANALYSIS; METHODOLOGY; MOTOR NEURON DISEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHODGKIN LYMPHOMA; OBESITY; ONLINE SYSTEM; OUTCOMES RESEARCH; OVARY CANCER; PANCREAS CANCER; POLICY; PUBLICATION; QUALITY CONTROL; QUANTITATIVE ANALYSIS; RANDOMIZATION; REVIEW; RHEUMATOID ARTHRITIS; SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW; ADULT; BIOMEDICAL TECHNOLOGY ASSESSMENT; CASE REPORT; COMPARATIVE STUDY; DRUG DELIVERY SYSTEM; EVALUATION STUDY; INFORMATION DISSEMINATION; ORGANIZATION; PUBLISHING; STENT; UNITED KINGDOM;

ADULT; ANTIBODIES, MONOCLONAL; ARTHRITIS, RHEUMATOID; CONGRESSES AS TOPIC; DRUG DELIVERY SYSTEMS; EVALUATION STUDIES AS TOPIC; GREAT BRITAIN; HUMANS; IMMUNOGLOBULIN G; INFORMATION DISSEMINATION; PUBLICATION BIAS; RECEPTORS, TUMOR NECROSIS FACTOR; STENTS; TECHNOLOGY ASSESSMENT, BIOMEDICAL;

EID: 85045482577     PISSN: 13665278     EISSN: None     Source Type: Journal    
DOI: 10.3310/hta10050     Document Type: Review

References (104)

1. Cook DJ, Guyatt GH, Ryan G, Clifton J, Buckingham L, Willan A, et al. Should unpublished data be included in meta-analyses? Current convictions and controversies. JAMA 1993;269:2749-53.
2. McAuley L, Pham B, Tugwell P, Moher D. Does the inclusion of grey literature influence estimates of intervention effectiveness reported in meta-analyses? Lancet 2000;356:1228-31.
3. Hopewell S, McDonald S, Clarke M, Egger M. Grey literature in meta-analyses of randomized trials of health care interventions (Review). In The Cochrane Database of Methodology Reviews (Issue 4). Chichester: John Wiley; 2002.
4. Mallet S, Hopewell S, Clarke M. The use of grey lierature in the first 1000 Cochrane reviews. In 4th Symposium on Systematic Reviews: Pushing the Boundaries, July 2002, Oxford. 2002.
5. Royle P, Milne R. Literature searching for randomized controlled trials used in Cochrane reviews: rapid versus exhaustive searches. Int J Technol Assess Health Care 2003;19:591-603.
6. Dickersin K. How important is publication bias? A synthesis of available data. AIDS Educ Prev 1997; 9 (1 Suppl):15-21.
7. Song F, Eastwood AJ, Gilbody S, Duley L, Sutton AJ. Publication and related biases. Health Technol Assess 2000;4(10):1-115.
8. Hopewell S. Time to publication for results of clinical trials (Review). In The Cochrane Database of Methodology Reviews (Issue 3). Chichester: John Wiley; 2001.
9. Scherer RW, Dickersin K, Langenberg P. Full publication of results initially presented in abstracts. A meta-analysis. JAMA 1994;272:158-62.
10. Scherer RW, Langenberg P, von Elm E. Full publication of results initially presented in abstracts (Cochrane Review). In The Cochrane Database of Methodology Reviews (Issue 2). Chichester: John Wiley; 2005.
11. Hutton JL, Williamson PR. Bias in meta-analysis due to outcome variable selection within studies. Applied Statistics 2000;49:359-70.
12. Chan AW, Hrobjartsson A, Haahr MT, Gotzsche PC, Altman DG. Empirical evidence for selective reporting of outcomes in randomized trials: comparison of protocols to published articles. JAMA 2004;291:2457-65.
13. Hahn S, Williamson PR, Hutton JL, Garner P, Flynn EV. Assessing the potential for bias in meta-analysis due to selective reporting of subgroup analyses within studies. Stat Med 2000;19:3325-36.
14. Williamson PR, Gamble C. Identification and impact of outcome selection bias in meta-analysis. Stat Med 2005;24:1547-61.
15. Piggott TD. Methods for handling missing data in research synthesis. In Cooper H, Hedges LV, editors. The handbook of research synthesis. Russell Sage: New York; 1994. pp. 163-75.
16. Egger M, Smith GD. Bias in location and selection of studies. BMJ 1998;316:61-6.
17. Royle P, Bain L, Waugh N. Systematic reviews of epidemiology in diabetes: finding the evidence. BMC Med Res Methodol 2005;5:2.
18. Royle P, Waugh N. Literature searching for clinical and cost-effectiveness studies used in health technology assessment reports carried out for the National Institute for Clinical Excellence appraisal system. Health Technol Assess 2003;7(34):iii, ix-x, 1-51.
19. Higginson JPT, Green S, editor, Planning the metaanalysis: methods of identifying trials (Appendix 11A, p. 218). In Cochrane Handbook for Systematic Reviews of Interventions 4.2.4 [updated March 2005] (Issue 2). Chichester: John Wiley; 2005.
20. Egger M, Juni P, Bartlett C, Holenstein F, Sterne J. How important are comprehensive literature searches and the assessment of trial quality in systematic reviews? Empirical study. Health Technol Assess 2003;7(1):1-76.
21. Savoie I, Helmer D, Green CJ, Kazanjian A. Beyond Medline: reducing bias through extended systematic review search. Int J Technol Assess Health Care 2003;19:168-78.
22. Suarez-Almazor ME, Belseck E, Homik J, Dorgan M, Ramos-Remus C. Identifying clinical trials in the medical literature with electronic databases: MEDLINE alone is not enough. Control Clin Trials 2000;21:476-87.
23. Cook AM, Finlay IG, Edwards AG, Hood K, Higginson IJ, Goodwin DM, et al. Efficiency of searching the grey literature in palliative care. J Pain Symptom Manage 2001;22:797-801.
24. Krzyzanowska MK, Pintilie M, Brezden-Masley C, Dent R, Tannock IF. Quality of abstracts describing randomized trials in the proceedings of American Society of Clinical Oncology meetings: guidelines for improved reporting. J Clin Oncol 2004;22:1993-9.
25. Bhandari M, Devereaux PJ, Guyatt GH, Cook DJ, Swiontkowski MF, Sprague S, et al. An observational study of orthopaedic abstracts and subsequent full-text publications. J Bone Joint Surg Am 2002;84-A(4):615-21.
26. Hopewell S. Assessing the impact of abstracts from the Thoracic Society of Australia and New Zealand in Cochrane reviews. Respirology 2003;8:509-12.
27. Jefferson TO, Alderson P, Davidoff F, Wager E. Editorial peer-review for improving the quality of reports of biomedical studies. In The Cochrane Database of Methodology Reviews (Issue 3). Chichester: John Wiley; 2001.
28. Tooher F, Middleton P, Griffin T, Pham C, Hopewell S. How different are conference abstracts of surgical RCTs from the subsequent full publication? In 12th Cochrane Colloquium, 2-6 October, Ontorio, Canada. 2004; Program & Abstract Book, p. 137.
29. Weintraub WH. Are published manuscripts representative of the surgical meeting abstracts? An objective appraisal. J Pediatr Surg 1987;22:11-13.
30. Chokkalingam A, Scherer R, Dickersin K Concordance of data between conference abstracts and full reports. In Cochrane Colloquium at Baltimore, Maryland. 1998.
31. Hopewell S, Clarke M, Askie L. Trials reported as abstracts and full publications: how do they compare? In 12th Cochrane Colloquium, 2-6 October. Ontorio, Canada. 2004; Program & Abstract Book, p. 77.
32. National Institute for Clinical Excellence. Guide to the technology appraisal process (reference N0514). URL: http://www.nice.org.uk/pdf/TAP.pdf. 2004.
33. National Institute for Clinical Excellence. Guide to the methods of technology appraisal (reference N0515). URL: http://www.nice.org.uk/pdf/TAP_Methods.pdf. 2004.
34. Khan K, Ter Riet G, Glanville J, Sowdon A, Kleijnen J. Undertaking systematic reviews of research on effectiveness. CRD's guidance for carrying out or commissioning reviews. CRD Report No. 4. 2nd ed. York: Centre for Reviews and Dissemination, University of York; 2001.
35. Clark W, Jobanputra P, Barton P, Burls A, The clinical and cost-effectiveness of anakinra for the treatment of rheumatoid arthritis in adults: a systematic review and economic analysis. Health Technol Assess 2004;8(18):iii-iv, ix-x, 1-105.
36. Chilcott J, Wight J, Lloyd Jones M, Tappenden P. The clinical effectiveness and cost-effectiveness of pioglitazone for type 2 diabetes mellitus: a rapid and systematic review. Health Technol Assess 2001;5(19):1-61.
37. Meads C, Salas C, Roberts T, Moore D, Fry-Smith A, Hyde C. Clinical effectiveness and cost-utility of photodynamic therapy for wet age-related macular degeneration: a systematic review and economic evaluation. Health Technol Assess 2003;7(9):v-vi, 1-98.
38. Shepherd J, Waugh N, Hewitson P. Combination therapy (interferon alfa and ribavirin) in the treatment of chronic hepatitis C: a rapid and systematic review. Health Technol Assess 2000;4(33):1-67.
39. Hill R, Bagust A, Bakhai A, Dickson R, Dundar, Y, Haycox A, et al. Coronary artery stents: a rapid systematic review and economic evaluation. Health Technol Assess 2004;8(35):iii-iv, 1-242.
40. Dalziel K, Round A, Stein K, Garside R, Price A. Effectiveness and cost-effectiveness of imatinib for first-line treatment of chronic myeloid leukaemia in chronic phase: a systematic review and economic analysis. Health Technol Assess 2004;8(28):iii, 1-120.
41. Jobanputra P, Barton P, Bryan S, Burls A. The effectiveness of infliximab and etanercept for the treatment of rheumatoid arthritis: a systematic review and economic evaluation. Health Technol Assess 2002;6(21):1-110.
42. McDonagh MS, Bachmann LM, Golder S, Kleijnen J, ter Riet G. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of glycoprotein IIb/IIIa antagonists in the medical management of unstable angina. Health Technol Assess 2000;4(30):1-95.
43. Clegg A, Scott DA, Sidhu M, Hewitson P, Waugh N. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer. Health Technol Assess 2001;5(32):1-195.
44. Forbes C, Shirran L, Bagnall AM, Duffy S, ter Riet, G. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of topotecan for ovarian cancer. Health Technol Assess 2001;5(28):1-110.
45. Lister-Sharp D, McDonagh MS, Khan KS, Kleijnen J. A rapid and systematic review of the effectiveness and cost-effectiveness of the taxanes used in the treatment of advanced breast and ovarian cancer. Health Technol Assess 2000;4(17):1-113.
46. Lloyd Jones M, Hummel S, Bansback N, Orr B, Seymour M. A rapid and systematic review of the evidence for the clinical effectiveness and cost-effectiveness of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer. Health Technol Assess 2001;5(25):1-128.
47. Burls A, Clark W, Stewart T, Preston C, Bryan S, Jefferson T, et al. Zanamivir for the treatment of influenza in adults: a systematic review and economic evaluation. Health Technol Assess 2002;6(9):1-87.
48. Moher D, Schachter HM. Potential solutions to the problem of conducting systematic reviews of new health technologies. CMAJ 2002;166:1674-5.
49. Juni P. Altman DG, Egger M. Systematic reviews in health care: Assessing the quality of controlled clinical trials. BMJ 2001;323:42-6.
50. Soares HP, Daniels S, Kumar A, Clarke M, Scott C, Swann S, et al. Bad reporting does not mean bad methods for randomised trials: observational study of randomised controlled trials performed by the Radiation Therapy Oncology Group. BMJ 2004;328:22-4.
51. Schachter HM, Kovesi T, Ducharme F, Langford S, Clifford T, Moher D. The challenges of early assessment: leukotriene receptor antagonists (technology report no. 19). Ottowa: Canadian Coordinating Office for Health Technology Assessment; 2001.
52. Meads C, Cummins C, Jolly K, Stevens A, Burls A, Hyde C. Coronary artery stents in the treatment of ischaemic heart disease: a rapid and systematic review. Health Technol Assess 2000;4(23):1-153.
53. Bagnall AM, Jones L, Ginnelly L, Lewis R, Glanville J, Gilbody S, et al. A systematic review of atypical antipsychotic drugs in schizophrenia. Health Technol Assess 2003;7(13):1-193.
54. Tramer MR, Reynolds DJ, Moore RA, McQuay HJ. Impact of covert duplicate publication on meta-analysis: a case study. BMJ 1997;315:635-40.
55. Whittington CJ, Kendall T, Fonagy P, Cottrell D, Cotgrove A, Boddington E. Selective serotonin reuptake inhibitors in childhood depression: systematic review of published versus unpublished data. Lancet 2004;363:1341-5.
56. Song FJ, Fry-Smith A, Davenport C, Bayliss S, Adi Y, Wilson JS, et al. Identification and assessment of ongoing trials in health technology assessment reviews. Health Technol Assess 2004;8(44):iii, 1-87.
57. Song, F, O'Meara S, Wilson P, Golder S, Kleijnen J. The effectiveness and cost-effectiveness of prophylactic removal of wisdom teeth. Health Technol Assess 2000;4(15):1-55.
58. Payne N, Chilcott J, McGoogan E. Liquid-based cytology in cervical screening: a rapid and systematic review. Health Technol Assess 2000;4(18):1-73.
59. Parkes J, Bryant J, Milne R. Implantable cardioverter defibrillators: arrhythmias. A rapid and systematic review. Health Technol Assess 2000;4(26):1-69.
60. Clegg A, Bryant J, Nicholson T, McIntyre L, De Broe S, Gerard K, et al. Clinical and cost-effectiveness of donepezil, rivastigmine and galantamine for Alzheimer's disease: a rapid and systematic review. Health Technol Assess 2001;5(1):1-137.
61. Stewart A, Sandercock J, Bryan S, Hyde C, Barton PM, Fry-Smith A, et al. The clinical effectiveness and cost-effectiveness of riluzole for motor neurone disease: a rapid and systematic review. Health Technol Assess 2001;5(2):1-97.
62. Jobanputra P, Parry D, Fry-Smith A, Burls A. Effectiveness of autologous chondrocyte transplantation for hyaline cartilage defects in knees: a rapid and systematic review. Health Technol Assess 2001;5(11):1-57.
63. Dinnes J, Cave C, Huang S, Major K, Milne R. The effectiveness and cost-effectiveness of temozolomide for the treatment of recurrent malignant glioma: a rapid and systematic review. Health Technol Assess 2001;5(13):1-73.
64. Lewis R, Whiting P, ter Riet G, O'Meara S, Glanville J. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of debriding agents in treating surgical wounds healing by secondary intention. Health Technol Assess 2001;5(14):1-131.
65. O'Meara S, Riemsma R, Shirran L, Mather L, ter Riet G. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of orlistat in the management of obesity. Health Technol Assess 2001;5(18):1-81.
66. Ward S, Morris E, Bansback N, Calvert N, Crellin A, Forman D, et al. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of gemcitabine for the treatment of pancreatic cancer. Health Technol Assess 2001;5(24):1-70.
67. Hyde C, Wake B, Bryan S, Barton P, Fry-Smith A, Davenport C, et al. Fludarabine as second-line therapy for B cell chronic lymphocytic leukaemia: a technology assessment. Health Technol Assess 2002;6(2):1-89.
68. Wake B, Hyde C, Bryan S, Barton P, Song F, Fry-Smith A, et al. Rituximab as third-line treatment for refractory or recurrent Stage III or IV follicular non-Hodgkin's lymphoma: a systematic review and economic evaluation. Health Technol Assess 2002;6(3):1-85.
69. Peters J, Stevenson M, Beverley C, Lim JN, Smith S. The clinical effectiveness and cost-effectiveness of inhaler devices used in the routine management of chronic asthma in older children: a systematic review and economic evaluation. Health Technol Assess 2002;6:1-167.
70. O'Meara S, Riemsma R, Shirran L, Mather L, ter Riet G. The clinical effectiveness and cost-effectiveness of sibutramine in the management of obesity: a technology assessment. Health Technol Assess 2002;6(6):1-97.
71. Clegg AJ, Colquitt J, Sidhu MK, Royle P, Loveman E, Walker A. The clinical effectiveness and cost-effectiveness of surgery for people with morbid obesity: a systematic review and economic evaluation. Health Technol Assess 2002;6(12):1-153.
72. Lewis R, Bagnall AM, Forbes C, Shirran E, Duffy S, Kleijnen J, et al. The clinical effectiveness of trastuzumab for breast cancer: a systematic review. Health Technol Assess 2002;6(13):1-71.
73. Lewis R, Bagnall AM, King S, Woolacott N, Forbes C, Shirran L, et al. The clinical effectiveness and cost-effectiveness of vinorelbine for breast cancer: a systematic review and economic evaluation. Health Technol Assess 2002;6(14):1-269.
74. Vale L, Wyness L, McCormack K, McKenzie L, Brazzelli M, Stearns SC. A systematic review of the effectiveness and cost-effectiveness of metal-on-metal hip resurfacing arthroplasty for treatment of hip disease. Health Technol Assess 2002;6(15):1-109.
75. Woolacott NF, Jones L, Forbes CA, Mather LC, Sowden AJ , Song FJ, et al. The clinical effectiveness and cost-effectiveness of bupropion and nicotine replacement therapy for smoking cessation: a systematic review and economic evaluation. Health Technol Assess 2002;6(16):1-245.
76. Cummins C, Connock M, Fry-Smith A, Burls A. A systematic review of effectiveness and economic evaluation of new drug treatments for juvenile idiopathic arthritis: etanercept. Health Technol Assess 2002;6(17):1-43.
77. Bryant J, Cave C, Mihaylova B, Chase D, McIntyre L, Gerard K, et al. Clinical effectiveness and cost-effectiveness of growth hormone in children: a systematic review and economic evaluation. Health Technol Assess 2002; 6(18):1-168.
78. Bryant J, Loveman E, Chase D, Mihaylova B, Cave C, Gerard K, et al. Clinical effectiveness and cost-effectiveness of growth hormone in adults in relation to impact on quality of life: a systematic review and economic evaluation. Health Technol Assess 2002;6(19):1-106.
79. Kaltenthaler E, Shackley P, Stevens K, Beverley C, Parry G, Chilcott J. A systematic review and economic evaluation of computerised cognitive behaviour therapy for depression and anxiety. Health Technol Assess 2002;6(22):1-89.
80. Forbes C, Wilby J, Richardson G, Sculpher M, Mather L, Riemsma R. A systematic review and economic evaluation of pegylated liposomal doxorubicin hydrochloride for ovarian cancer. Health Technol Assess 2002;6(23):1-119.
81. Robinson M, Ginnelly L, Sculpher M, Jones L, Riemsma R, Palmer S, et al. A systematic review update of the clinical effectiveness and cost-effectiveness of glycoprotein IIb/IIIa antagonists. Health Technol Assess 2002;6(25):1-160.
82. Garside R, Round A, Dalziel K, Stein K, Royle P. The effectiveness and cost-effectiveness of imatinib in chronic myeloid leukaemia: a systematic review. Health Technol Assess 2002;6(33):1-162.
83. Mowatt G, Vale L, Perez J, Wyness L, Fraser C, MacLeod A, et al. Systematic review of the effectiveness and cost-effectiveness, and economic evaluation, of home versus hospital or satellite unit haemodialysis for people with end-stage renal failure. Health Technol Assess 2003;7(2):1-174.
84. Clark W, Raftery J, Song F, Barton P, Cummins C, Fry-Smith A, et al. Systematic review and economic evaluation of the effectiveness of infliximab for the treatment of Crohn's disease. Health Technol Assess 2003;7(3):1-67.
85. Chilcott J, Lloyd Jones M, Wight J, Forman K, Wray J, Beverley C, et al. A review of the clinical effectiveness and cost-effectiveness of routine anti-D prophylaxis for pregnant women who are rhesus-negative. Health Technol Assess 2003;7(4):iii-62.
86. Calvert N, Hind D, McWilliams RG, Thomas SM, Beverley C, Davidson A. The effectiveness and cost-effectiveness of ultrasound locating devices for central venous access: a systematic review and economic evaluation. Health Technol Assess 2003;7(12):1-84.
87. Boland A, Dundar Y, Bagust A, Haycox A, Hill R, Mujica Mota R, et al. Early thrombolysis for the treatment of acute myocardial infarction: a systematic review and economic evaluation. Health Technol Assess 2003;7(15):1-136.
88. Cody J, Wyness L, Wallace S, Glazener C, Kilonzo M, Stearns S, et al. Systematic review of the clinical effectiveness and cost-effectiveness of tension-free vaginal tape for treatment of urinary stress incontinence. Health Technol Assess 2003;7(21):iii, 1-189.
89. Loveman E, Cave C, Green C, Royle P, Dunn N, Waugh N. The clinical and cost-effectiveness of patient education models for diabetes: a systematic review and economic evaluation. Health Technol Assess 2003;7(22):iii, 1-190.
90. Ward S, Kaltenthaler E, Cowan J, Brewer N, Clinical and cost-effectiveness of capecitabine and tegafur with uracil for the treatment of metastatic colorectal cancer: systematic review and economic evaluation. Health Technol Assess 2003;7(32):1-93.
91. Turner D, Wailoo A, Nicholson K, Cooper N, Sutton A, Abrams K. Systematic review and economic decision modelling for the prevention and treatment of influenza A and B. Health Technol Assess 2003;7(35):iii-iv, xi-xiii, 1-170.
92. Garside R, Stein K, Wyatt K, Round A, Price A. The effectiveness and cost-effectiveness of microwave and thermal balloon endometrial ablation for heavy menstrual bleeding: a systematic review and economic modelling. Health Technol Assess 2004;8(3):iii, 1-155.
93. Jones L, Hawkins N, Westwood M, Wright K, Richardson G, Riemsma R. Systematic review of the clinical effectiveness and cost-effectiveness of capecitabine (Xeloda) for locally advanced and/or metastatic breast cancer. Health Technol Assess 2004;8(5):iii, xiii-xvi, 1-143.
94. Czoski-Murray C, Warren E, Chilcott J, Beverley C, Psyllaki MA, Cowan J. Clinical effectiveness and cost-effectiveness of pioglitazone and rosiglitazone in the treatment of type 2 diabetes: a systematic review and economic evaluation. Health Technol Assess 2004;8(13):iii, ix-x, 1-91.
95. Bridle C, Palmer S, Bagnall AM, Darba J, Duffy S, Sculpher M, et al. A rapid and systematic review and economic evaluation of the clinical and cost-effectiveness of newer drugs for treatment of mania associated with bipolar affective disorder. Health Technol Assess 2004;8(19):iii-iv, 1-187.
96. Karnon J, Peters J, Platt J, Chilcott J, McGoogan E, Brewer N. Liquid-based cytology in cervical screening: an updated rapid and systematic review and economic analysis. Health Technol Assess 2004;8(20):iii, 1-78.
97. Dretzke J, Sandercock J, Bayliss S, Burls A. Clinical effectiveness and cost-effectiveness of prehospital intravenous fluids in trauma patients. Health Technol Assess 2004;8(23):iii, 1-103.
98. Dundar Y, Boland A, Strobl J, Dodd S, Haycox A, Bagust A, et al. Newer hypnotic drugs for the short-term management of insomnia: a systematic review and economic evaluation. Health Technol Assess 2004;8(24):iii-x, 1-125.
99. Mowatt G, Vale L, Brazzelli M, Hernandez R, Murray A, Scott N, et al. Systematic review of the effectiveness and cost-effectiveness, and economic evaluation, of myocardial perfusion scintigraphy for the diagnosis and management of angina and myocardial infarction. Health Technol Assess 2004;8(30):iii-iv, 1-207.
100. Knight C, Hind D, Brewer N, Abbott V. Rituximab (MabThera) for aggressive non-Hodgkin's lymphoma: systematic review and economic evaluation. Health Technol Assess 2004;8(37):iii, ix-xi, 1-82.
101. Jones L, Griffin S, Palmer S, Main C, Orton V, Sculpher M, et al., Clinical effectiveness and cost-effectiveness of clopidogrel and modified-release dipyridamole in the secondary prevention of occlusive vascular events: a systematic review and economic evaluation. Health Technol Assess 2004;8(38):iii-iv, 1-196.
102. Shepherd J, Brodin H, Cave C, Waugh N, Price A, Gabbay J. Pegylated interferon alpha-2a and -2b in combination with ribavirin in the treatment of chronic hepatitis C: a systematic review and economic evaluation. Health Technol Assess 2004;8(39):iii-iv, 1-125.
103. Main C, Palmer S, Griffin S, Jones L, Orton V, Sculpher M, et al. Clopidogrel used in combination with aspirin compared with aspirin alone in the treatment of non-ST-segment-elevation acute coronary syndromes: a systematic review and economic evaluation. Health Technol Assess 2004;8(40):iii-iv, xv-xvi, 1-141.
104. Colquitt JL, Green C, Sidhu MK, Hartwell D, Waugh N. Clinical and cost-effectiveness of continuous subcutaneous insulin infusion for diabetes. Health Technol Assess 2004;8(43):iii, 1-171.